PPARα agonists used to treat dyslipidemia have been shown to moderately induce the expression of ACADL and ECHS1 in rat liver [34], and in rat heart muscle PPARα agonists increase the expression of ECHS1 and reduce the expression of HADHA/B[35]. The gene discussed is ACADL; the disease is metabolic syndrome.